Belantamab mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
Belantamab mafodotin-blmf is now indicated for adult patients with relapsed or refractory myeloma who have received at least 4 prior therapies.
Remdesivir in the Treatment of COVID-19
On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).